Royalty Report: Drugs, Pharmaceuticals, Medical – Collection: 6876

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Medical
  • Supply
  • Wound Care
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6876

License Grant
The Company is party to certain royalty agreements relating to its intellectual property under which it pays certain fees.
License Property
Company has established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue. Over several years it has reached settlement and/or licensing Agreements with numerous companies infringing or seeking to avoid infringement of the Company’s patents. The underlying patents expired in late November 2009. These dates reflect the expiration of the License in the U.S., which coincides with the expiration of the Knighton Patent in the U.S.

The Licensor's current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:

• Process, formulation, and methods for utilizing platelet releasates to heal damaged tissue  
• Biomarkers for wound healing treatment efficacy  
• Peptides with anti-inflammatory properties  
• Peptides with angiogenic properties

The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies.

Field of Use
The field of use relates to the medical industry.

IPSCIO Record ID: 28449

License Grant
Licensor hereby grants to Licensee a non-exclusive license under the Licensed Patents to make, have made, use, import, sell, promote, market, offer for sale or otherwise transfer Royalty-Bearing Products in the Licensed Fields throughout the world.
License Property
The Company established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue. Over several years it has reached settlement and/or licensing Agreements with numerous companies infringing or seeking to avoid infringement of the Company’s patents. These dates reflect the expiration of the License in the U.S., which coincides with the expiration of the Knighton Patent in the U.S.  The Licensee agreement was effective 10/28/06 through 11/24/2009; controversy between the parties arising in connection with claims of infringement of U.S. Patent No. 5,165,938.  

The Licensor's current patent portfolio consists of more than 30 domestic and international patents that generally fall into the following families:
• Process, formulation, and methods for utilizing platelet releasates to heal damaged tissue  
• Biomarkers for wound healing treatment efficacy  
• Peptides with anti-inflammatory properties  
• Peptides with angiogenic properties

The above patent families encompass the Company’s AutoloGelTM System, CT-112 anti-inflammatory peptide, homologous growth factors, wound-healing biomarkers, and several other potential therapies.

Field of Use
Licensed Fields means any and all fields of use, worldwide.

IPSCIO Record ID: 6865

License Grant
Licensor hereby grants to Licensees a non-exclusive license under the Licensed Patents to make, have made, use, import, sell, promote, market, or offer for sale Licensed Products in the Licensed Fields throughout the Licensed Territories.
License Property
U.S. Patent No. 5,165,938 entitled Wound Healing Agents, issued 11/24/92

On 6/3/2005 it has reached settlement agreement LicenseeTechnologies for infringing or seeking to avoid infringement of the Company’s patents. The underlying patents expired in late November 2009.

Field of Use
Licensed Fields means any and all fields of use.

The Company has established its intellectual property rights arising from its process patents regarding the use of platelet releasates to heal damaged tissue.

IPSCIO Record ID: 26656

License Grant
A U.S. pharma has granted the worldwide rights to a U.S business unit of an Italian company the Knighton patent for all applications relating to the use of autologous platelet releasate therapies for healing purposes (wound-healing and tissue repair therapies).  U.S. Patent No. 5,165,938 entitled Wound Healing Agents.
License Property
5,165,938: A process for treating a wound of a live animal which comprises applying over the wound an effective amount of a treating composition containing the materials released by platelets during the platelet release reaction and facilitating healing of the wound.
Field of Use
Licensed Fields means any and all fields of use.

IPSCIO Record ID: 4236

License Grant
The Parties wish to jointly own all patents related to Fibroblast Growth Factor and the methods for producing and using FGF, whether such patents are developed jointly or individually by either party; and wish to License from one another exclusive rights to practice under the jointly owned patents in accordance with their respective plans for development and commercialization.

Licensor hereby agrees to assign to the Licensee a 50% ownership interest in the itemized patents and patent applications.

License Property
The Licensee will have a non-revocable, royalty-bearing, exclusive right within the territory to the Patent Rights in the Field, including the right to subLicense to third parties within the Field.

The Licensor will have a non-revocable, royalty free, exclusive right within the territory to the Patent Rights in all other fields outside of the Field, including the right to subLicense to third parties outside of the Field, encompassing any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions.

1. U.S. 6,268,178 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
2. U.S. 6,642,026 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.
3. U.S. 6,773,899 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
4. U.S. 6,794,162, entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
Pending US Patent Applications 1.. U.S. 10/649,480 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis; published as US Patent Application No. US 2004/0115769 .

1. International Patent Application No. PCT/US00/40020, published as International Publication No. WO 00/71731 A2 on November 30, 2000 entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.
2. International Patent Application No. PCT/US01/25537, published as International Publication No. WO 02/14471 A2 on February 21, 2002 entitled Method of Producing Biologically Active Human Acidic Fibroblast Growth Factor and its Use in Promoting Angiogenesis.
3. International Patent Application No. PCT/US01/25477, published as International Publication No. WO 02/14468 A2 on February 21, 2002, entitled Phage-Dependent Super-Production of Biologically Active Protein and Peptides.

Field of Use
Field shall encompass any angiogenic or wound healing compositions, (including in particular, but without limitation, all FGF species, fragments, derivatives, and analogs thereof, nucleic acid sequences encoding angiogenic or wound healing proteins/peptides), vectors and host cells comprising said DNA sequences, methods of making the angiogenic or wound healing compositions, and methods of inducing angiogenesis or wound healing employing the said compositions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.